期刊文献+

他克莫司缓释胶囊在心血管安全性方面临床价值的探讨

原文传递
导出
摘要 他克莫司(商品名:普乐可复)是强效免疫抑制剂,它的出现显著提高了移植受者的长期存活。随着移植存活时间延长,心血管事件对受者的影响越来越引人关注。他克莫司缓释胶囊(商品名:新普乐可复)为1次/d的他克莫司缓释剂型,旨在提高血药浓度稳定性和受者依从性,从而改善移植受者的长期结果。本文即将探讨他克莫司缓释剂型能否带来心血管方面的临床获益。
出处 《中华器官移植杂志》 CAS CSCD 北大核心 2013年第1期64-64,共1页 Chinese Journal of Organ Transplantation
  • 相关文献

参考文献6

  • 1Ishibashi M, Yoshida K, Ozono S, et al. Experimental study of tacrolimus immunosuppression on the mode of administration: efficacy of constant intravenous infusion avoiding C(max). Transplant Proc, 2001, 33(1-2):559-560.
  • 2Mecule A, Poli L, Nofroni I, et al. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. Transplant Proc, 2010, 42(4):1317-1319. doi: 10. 1016/j. transproceed. 2010. 03. 123.
  • 3Uchida, J. , et al. , Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism. Transplant Proc, 2012. 44(1): 128-133.
  • 4Kurnatowska I, Krawczyk J, Oleksik T, et al. Taerolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus. Transplant Proc, 2011, 43(8):2954-2956. doi: 10. 1016/j. transproceed. 2011.08. 021.
  • 5Tsuchiya T, Ishida K, Ito S, et al. Effect of conversion from twice-daily to once-daily tacrolimus on glucose intolerance in stable kidney transplant recipients. Transplant Proc, 2012, 44(1) : 118-120. doi: 10. 1016/j. transproceed. 2011.11. 027.
  • 6Truneeka P, Boillot O, Seehofer D, et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant, 2010, 10(10) :2313-2323. doi: 10. 1111/j. 1600-6143. 2010. 03255. x.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部